U.S. markets close in 16 minutes
  • S&P 500

    4,365.12
    -32.82 (-0.75%)
     
  • Dow 30

    34,040.37
    -225.00 (-0.66%)
     
  • Nasdaq

    13,698.60
    -70.32 (-0.51%)
     
  • Russell 2000

    2,014.98
    +27.06 (+1.36%)
     
  • Crude Oil

    83.60
    -1.54 (-1.81%)
     
  • Gold

    1,839.20
    +7.40 (+0.40%)
     
  • Silver

    23.91
    -0.41 (-1.71%)
     
  • EUR/USD

    1.1326
    -0.0028 (-0.25%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • GBP/USD

    1.3487
    -0.0058 (-0.43%)
     
  • USD/JPY

    113.8800
    +0.2250 (+0.20%)
     
  • BTC-USD

    36,420.87
    +1,214.83 (+3.45%)
     
  • CMC Crypto 200

    829.44
    +18.84 (+2.32%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,588.37
    +66.11 (+0.24%)
     

Ziopharm Oncology to Report Third Quarter Financial Results on November 8, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ZIOP

HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results.

The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Ziopharm website at www.ziopharm.com. After the live webcast, the event will be archived on Ziopharm’s website for approximately 90 days after the call.

About Ziopharm Oncology, Inc.
Ziopharm is a clinical-stage oncology-focused cell therapy company, developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer platform and its unique cancer hotspot Library, covering common tumor-related mutations in key oncolytic genes such as KRAS and TP53. The Company has clinical and strategic collaborations with the National Cancer Institute and The University of Texas MD Anderson Cancer Center. For more information, please visit www.ziopharm.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
Alex.lobo@sternir.com